Mantle Cell Lymphoma: Is Routine Imaging Worth It?
"Rethinking surveillance strategies for patients in remission to reduce anxiety and improve outcomes."
Following lymphoma treatment, regular check-ups are crucial. However, there's debate on the best approach. These visits aim to spot any long-term side effects from treatment and check for recurrence through physical exams, lab tests, and often, imaging. For many, these checks offer reassurance.
The peace of mind after a check-up is valuable. However, using routine imaging to detect early relapse can raise anxiety levels around scan times. While doctors want to catch any recurrence early—some studies suggest early detection leads to better outcomes—routine follow-up strategies in lymphoma are being questioned.
New research is challenging the status quo of routine imaging for lymphoma, especially in specific subtypes like Mantle Cell Lymphoma (MCL). This article explores these findings, offering a fresh perspective on post-remission care.
A Rare Subtype With Divergent Trends
Mantle cell lymphoma (MCL) is a rare, aggressive variant of non-Hodgkin lymphoma. While non-Hodgkin lymphoma incidence has declined roughly 1% per year since 2015, it is not known whether that trend holds true for MCL. Investigators examining the Surveillance, Epidemiology and End Results (SEER) 17 database, which includes MCL data collected from 12 US states between 2000 and 2013, and a separate SEER Research Plus Data set (17 Registries, Nov 2022 Sub, 2000-2020) covering MCL cases diagnosed after age 20 (Lymphoid neoplasm recode 2 (a)2.1.3) have sought to clarify these trends. Data on complete response rates following induction chemotherapy in MCL from the Indian subcontinent remain scarce, and the Lymphoma Research Foundation's 21st Mantle Cell Lymphoma Scientific Consortium and Workshop, held in April 2025, gathered researchers to discuss the latest developments in MCL characterization and treatment.
Routine Evaluation Is Common; Its Value Is Unsettled
Standard evaluation of suspected lymphoproliferative disease generally begins with tissue biopsy, and staging and follow-up commonly rely on imaging such as computed tomography or PET scans. The specific value of that routine imaging, particularly surveillance imaging after treatment, is not firmly established in mantle cell lymphoma. No single widely accepted imaging protocol for MCL exists, and practice often rests on extrapolation from other lymphoma types. Because the evidence base is limited, the question of whether routine imaging is worth its cost and radiation exposure remains genuinely open.
From 'Centrocytic' to a Distinct Entity
Mantle cell lymphoma was recognized as a distinct entity over several decades. In 1964, Lennert first described the disease as 'centrocytic' lymphoma; in 1982, Weisenburger proposed the concept of 'mantle-zone lymphoma'; and in 1985, Pileri et al. reported 18 cases of small B-cell lymphomas displaying a mantle-fashion growth around reactive germinal centers. Sources differ on who coined the term 'mantle cell lymphoma': one credits Raffeld and Jaffe with first adopting it in 1991, while another attributes it to Banks in 1992, and the entity was formally included in classification schemes in 1994. The malignant cells arise in the mantle zone of the lymph node, have small to medium-sized, often indented or cleaved nuclei, and typically stain positively with CD5, CD20, cyclin D1, and FMC7. MCL accounts for roughly 6% of non-Hodgkin's lymphoma cases, and for years frontline treatment was dictated by age and fitness for intensive chemoimmunotherapy and autologous stem cell transplantation, approaches that yielded high response rates but carried treatment-related morbidity and disease relapse.
The Dilemma of Routine Imaging in Lymphoma Follow-Up
Studies on aggressive non-Hodgkin lymphoma and Hodgkin lymphoma (HL) show that surveillance efforts benefit a small fraction of patients since the goal is to cure for the majority. In diffuse large B-cell lymphoma (DLBCL) and HL, less than 5% of patients undergoing routine imaging find a relapse through this method. This exposes the remaining 95% to potential harm.
- Increased anxiety related to scan anticipation.
- Potential for secondary cancers due to radiation exposure.
- Risk of false positives, leading to more testing.
An Evolving, Mostly Early-Stage Literature
Recent research on mantle cell lymphoma continues to evolve, though its pace and focus vary considerably depending on the particular studies in question. Much of the recent work appears to center on better characterizing the disease, refining treatment approaches, and improving outcomes across patient populations. A large share of this literature is early-stage or observational, so findings should be interpreted cautiously rather than treated as settled practice. As more data accumulate, the evidence base for specific strategies, including imaging-related questions, is likely to sharpen.
A Historically Poor Prognosis That Is Improving
Recent reviews describe mantle cell lymphoma as a biologically and clinically heterogeneous B-cell malignancy with a historically poor prognosis. The New England Journal of Medicine notes that MCL accounts for 5 to 7% of all lymphomas and, although survival is improving, it has historically been associated with a poor outcome. The clinical course is variable, ranging from indolent, asymptomatic forms to aggressive subtypes with early treatment failure, and MCL is widely described as an incurable disease with an aggressive course in which most patients eventually relapse after chemotherapy. One practical limitation is that targeted therapies were approved based on clinical trial data, yet real-world data on relapsed/refractory MCL are scarce and scattered, complicating routine management decisions.
Head-to-Head Comparisons Are Largely Missing
A lack of direct comparative evidence makes formal comparison across mantle cell lymphoma management strategies difficult. Much of what is known derives from heterogeneous observational cohorts and single-institution experiences rather than rigorous randomized head-to-head trials. Consequently, claims about the superiority of one approach over another should be read as tentative rather than definitive. It is precisely this kind of question, including the value of routine imaging, where more robust comparative data would help clinicians and patients.
Rethinking the Approach to MCL Surveillance
A recent study by Guidot et al. (2017) found routine imaging has limited value for MCL patients in remission. In 37% of patients in the study, relapse was found by routine imaging. There was no outcome differences between imaging detected relapse vs. clinical relapse. Only 4% of routine imaging led to relapse diagnosis, showing limited routine imaging for MCL.
Recurring Themes, No Settled Consensus
Across the available literature, a few themes recur: mantle cell lymphoma is rare, heterogeneous in behavior, and its management remains in flux. Commentary tends to emphasize risk-adapted, individualized care rather than one-size-fits-all protocols, but there is no consensus synthesis that definitively resolves open questions such as the value of routine imaging. Because the evidence is limited and partly conflicting, conclusions should be treated as provisional and weighed against each patient's specific circumstances.
Toward Precision, With Open Questions
The future of mantle cell lymphoma research appears to point toward more precise, biology-driven approaches, though the trajectory is uncertain. Likely directions include better risk stratification and the integration of molecular data into clinical decision-making. Whether routine surveillance imaging will remain part of that future, or be replaced by less burdensome monitoring, depends on evidence that has not yet matured. For now, these possibilities remain prospects rather than settled directions.
Overtesting, Value, and Trade-Offs
Questions about routine imaging in mantle cell lymphoma sit within broader debates about healthcare value and the balance between reassurance and the harms of overtesting. Cost, radiation exposure, false positives, and patient anxiety are inherent trade-offs that care systems struggle to quantify. Individual patient values and circumstances matter, and there is no single answer that serves everyone. These systemic challenges reinforce why rigorous studies tied to real-world outcomes are needed.
Real-World Patients, Personal Journeys
Human impacts emerge sharply in real-world data. One study tracked 518 MCL patients across 5 major Chinese Hematology Centers, delineating disease characteristics, initial treatment patterns, and survival outcomes. A Cleveland Clinic case involved a previously healthy woman in her 60s diagnosed with high-risk MCL who, about a year after enrolling in a clinical trial combining a monoclonal antibody, a BTK inhibitor, and a BCL-2 inhibitor, achieved complete remission with minimal side effects. A high-complexity referral center in a middle-income Latin American country is contributing real-world evidence on clinical characteristics, treatment patterns, and overall survival in routine practice, while researchers suggest that integrating clinically relevant genetic alterations such as TP53 and Ki-67 into registries could improve understanding of outcomes in this uncommon, t(11;14)-driven B-cell lymphoma. The human reality is one of variable journeys, from a 51-year-old man diagnosed with small cell lymphoma via biopsy of his right inguinal lymph node to patients described as facing aggressive disease and early treatment failure.
More sensitive methods for detecting minimal residual disease, like multiparameter flow cytometry and PCR-based approaches, are emerging. These techniques can predict early relapse and drive preemptive therapy. However, they aren't widely available, and only some labs can perform them in a standard way.
For now, in the absence of clinical signs of disease progression, routine imaging in MCL offers little benefit, mirroring what's been found in other aggressive lymphomas. As methods evolve, the focus is shifting toward more tailored, less invasive surveillance strategies. New approaches like digital droplet PCR and next-generation sequencing are promising to refine post-remission surveillance.